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The primary structure of inter-a-trypsin inhibitor is partially elucidated, but controversy about the construction of the 
polypeptide backbone still exists. We present evidence suggesting that inter-a-trypsin inhibitor represents a novel plasma 
protein structure with two separate polypeptide chains covalently crosslinked only by carbohydrate (chondroitin 
sulphate) 
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1. INTRODUCTION 
Inter-a-trypsin inhibitor (ITI) is a serine pro- 
tease inhibitor present in human serum and plasma 
(0.4-0.5 g/l) [l]. The primary structure of IT1 has 
recently been reviewed [2] as a single polypeptide 
chain of Mr 180000 with the inhibitory activity 
located near the N-terminal. The N-terminal 
amino acid sequence of IT1 is identical to the se- 
quence found in inhibitory active IT1 metabolites 
normally present in plasma (ITI-derivatives) and 
urine (UTI) [3]. UT1 and IT1 derivatives are 
assumed to be produced in vivo by limited pro- 
teolysis of IT1 in the N-terminal region of the 
polypeptide chain [3]. A protease responsible for 
these cleavages has not been identified, and high 
concentrations of proteases are generally needed 
for in vitro fragmentation of IT1 [4]. 
Covalently bound glycosaminoglycan (chon- 
droitin sulphate) has been identified in purified 
UT1 [5]. Digestion of UT1 (Mr 44000) with chon- 
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droitinase (EC 4.2.2.4) removes the glycos- 
aminoglycan without proteolytic modification, 
giving rise to UT1 c (Mr 26000) [6]. 
The hypothesis that IT1 is comprised of a single 
polypeptide chain has been challenged [7] by the 
detection of mRNA from baboon liver, with 
translation products corresponding to two im- 
munochemically distinct polypeptide chains both 
related to ITI. cDNA clones from human liver 
libraries with nucleic acid sequences coding for 
well-known amino acid sequences of IT1 has 
recently been isolated [g-lo]. One of these clones 
contains the complete sequence of UT1 [9] ter- 
minated by a stop codon. These results indicate 
that human IT1 is not a single chain structure but 
composed of at least two polypeptide chains, one 
of which is identical to the polypeptide chain of 
UTI. 
It is generally accepted, however, that IT1 
migrates as an undissociable molecule in SDS- 
PAGE even after treatment with reducing agents 
[2]. Thus, if more than one polypeptide chain is 
present in ITI, a covalent link different from a 
disulphide bridge must exist between the chains. 
In this paper we present evidence suggesting that 
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inter-cu-trypsin i hibitor represents a novel plasma 
protein structure with two polypeptide chains 
covalently crosslinked only by carbohydrate (chon- 
droitin sulphate). 
2. MATERIALS AND METHODS 
2.1. Reagents and chemicals 
2.1.1. Enzymes 
Ovine testicular hyaluronidase (EC 3.2.1.35, Calbiochem 
no.38594, spec. act. 6775 N.F. units/mg), bovine testicular 
hyaluronidase (LEO Denmark no.001412, spec. act. > 100 N.F. 
units/mg), hyaluronidase from Streptomyces hyaiurobticus 
(Sigma no.1136) and chondroitinase ABC from Proteus 
vulgaris (EC 4.2.2.4, Sigma no.2905 spec. act. 1.5 units/mg). 
2.1.2. Purified proteins 
Human ITI (2 mg/ml) was purified from fresh normal 
EDTA plasma by polyethyleneglycol precipitation, anion- 
exchange chromatography and gel filtration (unpublished). 
Separation of ITI fragments generated by hyaluronidase diges- 
tion was achieved by gel filtration on a TSK G3OOOSW column 
at a flow rate of 0.4 ml/min in 0.1 M CHsCOONH4, pH 7.0. 
Human serum albumin from Kabi Vitrum, Stockholm, Sweden. 
Rabbit anti-human IT1 from Dakopatts, Denmark (code 
A 301). Molecular mass standards were rabbit muscle myosin 
(200 kDa), fl-galactosidase (116 kDa), rabbit muscle 
phosphorylase b (94 kDa), bovine serum albumin (67 kDa), 
ovalbumin (43 kDa), carbonic anhydrase (30 kDa) and soybean 
trypsin inhibitor (20 kDa). 
2.1.3. Protease inhibitors 
Benzamidine hydrochloride (Sigma no.B-6506), p-chloromer- 
curibenzoic acid (Sigma no.C-4378), phenylmethylsulfonyl 
fluoride (Sigma no.P-7626), 6-aminohexanoic acid (Merck 
Art.800145), EDTA (Merck Art 8418). 
2.2. Enzymatic digestions 
Enzymatic digestions were performed at 37°C with 5 vols 
normal human serum or purified IT1 mixed with 3 vols reaction 
buffer and 2 vols enzyme preparation. Aliquots were 
withdrawn after 10, 20, 40, 80 and 160 min and frozen im- 
mediately until analysed. Reaction buffer contained 20 mM 
EDTA, 0.25 M NaCI, 0.1 M CHsCOONa, pH 4.8, in 
hyaluronidase digestions, and 20 mM EDTA, 0.25 M NaCI, 
0.25 M Tris, 0.18 M CHsCOONa, 0.05% human albumin, pH 
8.0, in chondroitinase digestions. 
Enzyme preparations were preincubated 30 min, 25’C in 
0.1 M CHrCOONa, 0.25 M NaCl, pH 4.8, containing the pro- 
tease inhibitors 25 mM benzamidine hydrochloride, 20 mM 
phenylmethylsulfonyl fluoride, 2.5 mM p-chloromercuri- 
benzoic acid and 50 mM 6-aminohexanoic acid. Enzyme con- 
centrations during preincubation were 50 N.F. units/ml for 
ovine testicular hyaluronidase, 25 N.F. units/ml for bovine 
testicular hyaluronidase, 31 N.F. units/ml for hyaluronidase 
from Streptomyces hyalurolyticus and 3.3 U/ml for chondro- 
itinase ABC. 
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2.3. Immunoelectrophoresis and SDS-PAGE 
Crossed immunoelectrophoresis according to Hoiby and Ax- 
elsen [l l] and crossed-line immunoelectrophoresis according to 
Krell [12] were performed in Tris/barbital buffer, pH 8.6, 
against rabbit anti-human ITI, 1.4 ,41/cm2. 
2.4. Solubilization of immunoprecipitates 
Immunoprecipitates were isolated from unstained crossed im- 
munoelectrophoresis. Precipitates were cut out separately, 
eluted 180 min at 37°C in a buffer containing 3% SDS and 
40 mM dithioerythritol. The eluates were concentrated in 
Amicon B 15 concentration cells before application in 
SDS-PAGE. 
2.5. Amino terminal sequence determination 
Automatic sequencing was performed on a protein sequencer 
(Applied Biosystems, model 477 A) using the program 
‘NORMAL-l’ supplied with the instrument. The released 
phenylthiohydantoin amino acid derivatives were identified and 
quantified by on-line HPLC analysis (Applied Biosystems, 
model 120 A) on a reversed-phase column (C 18). 
3. RESULTS AND DISCUSSION 
3.1. Enzymatic digestion of ITI in serum 
The immunoprecipitation pattern of IT1 in nor- 
mal human serum is shown in fig.la. The main 
precipitate represents intact ITI, and the minor 
with a higher electrophoretic mobility represents 
IT1 derivatives [14]. This precipitation pattern re- 
mained unchanged when serum was analysed after 
incubation for 160 min at the reaction conditions 
applied in the enzymatic digestions but without 
added enzyme. 
Normal human serum digested by hyaluronidase 
from ovine testes (molar ratio: enzyme/IT1 - 
1: 50) reveals the IT1 degradation pattern shown in 
fig.1. The precipitate of intact IT1 gradually 
decreases with the concomitant appearance of two 
new precipitates: one of lower and one of higher 
electrophoretic mobility. Digestion of intact IT1 is 
completed in 160 min (fig.lf), with two im- 
munochemically non-identical components as end 
products. This precipitation pattern does not 
change with further digestion. 
In addition to the digestion presented in fig.1, 
other endoglycosidases with various glycos- 
aminoglycan specificities were examined for their 
ability to cleave ITI. Hyaluronidase from bovine 
testes, acting on both hyaluronic acid and chon- 
droitin sulphate [ 15,161, and chondroitinase ABC, 
selective for chondroitin sulphate [17], both cleav- 
ed IT1 with the same result as shown in fig. 1. In the 
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Fig.t. Serum digested by hyaluronidase, analysed in crossed immunoelectrophoresis against anti-human ITI. Samples (15 rl): (a) 
normal human serum diluted 1: 2; (b-f) serum digested by hyaluronidase for 10 min (b), 20 min (c), 40 min (d), 80 min (e) and 
160 min (f). 
presence of chondroitin sulphate ABC (5 mg/ml) 
these cleavages were inhibited. In contrast to the 
above mentioned enzymes hyaluronidase from 
Streptomyces hyalurolyticus, selective for 
hyaluronic acid [18] did not cleave ITI. According 
to the selectivity of the applied enzymes these 
results suggest the existence of a chondroitin 
sulphate crosslinkage between two polypeptide 
chains in ITI. 
3.2. Enzymatic digestion of purified ITI 
The existence of two polypeptide chains in IT1 is 
further confirmed by digestion of purified IT1 with 
ovine testicular hyaluronidase (fig.2, lanes 3-8). 
Purified reduced IT1 appears in SDS-PAGE as a 
single band of MI > 200000 (lanes 3 and 4). As the 
digestion proceeds, IT1 gradually decreases (lanes 
5-8) with the concomitant appearance of two new 
components of M, 160000 (heavy chain) and M, 
26000 (light chain). A faint transient band of low 
mobility (lanes 5-8) is possibly due to partially 
digested chondroitin sulphate. 
An identical pattern was observed when the 
serum samples from the digestion shown in fig.1 
were subjected to SDS-PAGE and subsequent im- 
munoblotting using a polyclonal anti-human IT1 
as primary antibody (not shown). 
The relation between the heavy/light chain in 
SDS-PAGE and the slow/fast migrating com- 
ponents in immunoelectrophoresis i  verified in 
fig.2 (lanes 10-12). The applied samples are 
solubilized immunoprecipitates representing intact 
IT1 (lane lo), slow migrating component (lane 11) 
and fast migrating component (lane 12). Intact IT1 
appears to have the same molecular mass as 
purified undigested ITI. The slow migrating com- 
ponent and the heavy chain generated by en- 
zymatic digestion are apparently identical 
according to SDS-PAGE. The supposed relation- 
ship between the fast migrating component and the 
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Fig.2. SDS-PAGE of purified IT1 and solubilized immunoprecipitates before and after digestion with testicular hyalmonidase. Lanes: 
1, molecular mass standards; 2, testicular hyaluronidase (same amount as in lanes 5-8); 3, purified ITI; 4, purified IT1 incubated 
without added enzyme for 160 min at conditions used in the digestion; 5-8, IT1 digested by testicular hyaluronidase for 10 min (5), 
20 min (6), 40 min (7) and 160 min (8); 9, molecular mass standards; 10, solubilized immunoprecipitate of intact ITI; 11, solubilized 
immunoprecipitate of slow migrating component; 12, solubilized immunoprecipitate of fast migrating component; 13, molecular mass 
standards. The amount of IT1 antigen in lanes 3-8 is 8 pg. 
light chain cannot be established by this technique, 
due to the weak intensity of the light chain, which 
is further masked by a diffuse zone (Mr 
25000-30000) originating from the rabbit an- 
tibodies (light chains). 
3.3. Isolation of heavy and light chain 
Separation of the heavy and light chain was per- 
formed by gel filtration of purified IT1 digested by 
hyaluronidase. Two components of I%& 160000 and 
26000 were isolated and their immunochemical 
relationship with the two components generated in 
serum are confirmed by crossed-line immunoelec- 
trophoresis (fig.3). Apparently the isolated heavy 
chain is related to the slow migrating component, 
and the light chain to the fast migrating com- 
ponent .
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If normal human urine is applied to the in- 
termediate gel, a precipitation pattern identical to 
fig.3b is obtained. 
3.4. N-terminal sequence determination 
In order to finally establish the connection be- 
tween intact IT1 and hyaluronidase-generated 
heavy chain and light chain, these components 
were subjected to automatic Edman degradation. 
The amino acid sequences obtained are shown in 
table 1. 
It is evident that intact human IT1 possess two 
N-terminal sequences present in equimolar 
amounts. The N-terminal amino acid sequence of 
the purified heavy chain and light chain completely 
account for the entire double sequence obtained 
for ITI. The N-terminus of the light chain is iden- 
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Fig.3. Crossed-line immunoelectrophoresis illustrating immunochemical relationship between the isolated heavy/light chain of ITI, 
and the fast/slow migrating component. Samples applied in the wells are serum digested by hyaluronidase (as in fig.lf). Intermediate 
gels contained 3 peg purified heavy chain (a) or 4 pg purified light chain (b). 
tical to that of UT1 [3] as far as residue number 20, 
where sequencing was terminated. 
Based upon the selectivity of the applied en- 
zymes, and on our analysis of the generated reac- 
tion products, we propose that human IT1 is 
composed of two distinct polypeptide chains, one 
Table 1 
N-terminal amino acid sequences obtained from intact IT1 and 
purified ITI-fragments generated by hyaluronidase digestion 
Residue number 12 3 4 5 6 7 8 9 101112 
Intact IT1 AVLPQEEEG-GG 
SLPGEK-QAVDT 
MME- 
Light chain AVLPQEEEG-GG 
Heavy chain SLPGEKEQAVDT 
MME- 
Roughtly equimolar amounts of PTH derivatives were 
recovered at step 1, 2 and 5 in the continuous double sequence 
obtained from intact ITI. Amino acid sequence analysis of 
isolated heavy chain as well as heavy chain forming part of ITI, 
unambiguously identified two residues in step 9-l 1, whereas 
the preceding steps stated a single residue only. Repetitive yields 
of amino acid PTH derivatives were 92% (light chain) and 96% 
(heavy chain). (-) Indicates that no obvious PTH amino acid, 
other than those stated, were recovered in the steps concerned 
light chain and one heavy chain. The two chains 
are covalently crosslinked by chondroitin sulphate, 
and the light chain seems to be identical to the 
polypeptide chain of UTI. We know of no other 
plasma protein where two polypeptide chains are 
covalently connected exclusively by carbohydrate. 
The physiological significance of this structural 
feature is unknown. 
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